Pretax income is the income that a company earns before paying income taxes. AN2 Therapeutics's pretax income for the
three
months ended in Mar. 2024 was $-16.62 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-66.03 Mil.
AN2 Therapeutics's pretax margin was %.
AN2 Therapeutics Pre-Tax Income Historical Data
The historical data trend for AN2 Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AN2 Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, AN2 Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AN2 Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AN2 Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where AN2 Therapeutics's Pre-Tax Income falls into.
AN2 Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
AN2 Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AN2 Therapeutics (NAS:ANTX) Pre-Tax Income Explanation
AN2 Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AN2 Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of AN2 Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
AN2 Therapeutics (AN2 Therapeutics) Business Description
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ANTX has been successfully added to your 